110 related articles for article (PubMed ID: 18443123)
1. Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
Mallalieu NL; Lennon S; Liu M; Kirkpatrick C; Robson R; Luedin E; Davies BE
Antimicrob Agents Chemother; 2008 Jul; 52(7):2360-6. PubMed ID: 18443123
[TBL] [Abstract][Full Text] [Related]
2. Lack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
Mallalieu NL; Lennon S; Guy T; Liu M; Luedin E; Davies BE
Br J Clin Pharmacol; 2009 Apr; 67(4):469-72. PubMed ID: 19371322
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
Nandy P; Samtani MN; Lin R
Antimicrob Agents Chemother; 2010 Jun; 54(6):2354-9. PubMed ID: 20385854
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
Gretler DD; Guerciolini R; Williams PJ
Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
[TBL] [Abstract][Full Text] [Related]
5. Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data.
Shibayama T; Matsushita Y; Kurihara A; Hirota T; Ikeda T
Xenobiotica; 2007 Jan; 37(1):91-102. PubMed ID: 17178636
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment.
Weller S; Jones LS; Lou Y; Peppercorn A; Ng-Cashin J
Antimicrob Agents Chemother; 2013 Jul; 57(7):2967-71. PubMed ID: 23587959
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment.
Matsuo Y; Ishibashi T; Kubota R; Wajima T
J Infect Chemother; 2015 Feb; 21(2):123-9. PubMed ID: 25487084
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.
Dale GE; Halabi A; Petersen-Sylla M; Wach A; Zwingelstein C
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012756
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.
Shibayama T; Matsushita Y; Hirota T; Ikeda T; Kuwahara S
Antimicrob Agents Chemother; 2006 Dec; 50(12):4186-8. PubMed ID: 17043123
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.
Hoover RK; Alcorn H; Lawrence L; Paulson SK; Quintas M; Luke DR; Cammarata SK
J Clin Pharmacol; 2018 Jun; 58(6):814-822. PubMed ID: 29578585
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
Tanaka K; Mikamo H; Nakao K; Ichiishi T; Goto T; Yamagishi Y; Watanabe K
Antimicrob Agents Chemother; 2009 Jan; 53(1):319-22. PubMed ID: 18955522
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
14. Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem.
Shibayama T; Yamamura N; Matsushita Y; Tokui T; Hirota T; Ikeda T
Xenobiotica; 2006 Dec; 36(12):1273-87. PubMed ID: 17162472
[TBL] [Abstract][Full Text] [Related]
15. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF).
Hidaka S; Goto K; Hagiwara S; Iwasaka H; Noguchi T
Yakugaku Zasshi; 2010 Jan; 130(1):87-94. PubMed ID: 20046071
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
Ishizuka H; Yoshiba S; Yoshihara K; Okabe H
J Clin Pharmacol; 2011 Feb; 51(2):243-51. PubMed ID: 20197485
[TBL] [Abstract][Full Text] [Related]
18. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects.
Kozawa O; Uematsu T; Matsuno H; Niwa M; Takiguchi Y; Matsumoto S; Minamoto M; Niida Y; Yokokawa M; Nagashima S; Kanamaru M
Antimicrob Agents Chemother; 1998 Jun; 42(6):1433-6. PubMed ID: 9624490
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.
MacFarland R; Hard ML; Scarborough R; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 Jan; 16(1):95-101. PubMed ID: 19748593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
